NSCLC

ASCO 2017: Breast cancer next target for Keytruda

May 18, 2017

Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.

ASCO 2017: Breast cancer next target for Keytruda

https://pharmaphorum.com/views-and-analysis/asco-2017-breast-cancer-keytruda/

BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cancer patients

April 25, 2017

Bristol-Myers Squibb is teaming up with France’s Transgene to combine Opdivo with investigational therapeutic vaccine TG4010 in lung

BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cancer patients

https://pharmaphorum.com/news/bms-looks-opdivo-cancer-vaccine-combination-regain-ground-nsclc/

Roche’s Alecensa beats Xalkori in lung cancer head-to-head

April 10, 2017

Roche’s new targeted lung cancer treatment Alecensa has shown itself to be superior to Pfizer’s established rival Xalkori

Roche’s Alecensa beats Xalkori in lung cancer head-to-head

https://pharmaphorum.com/news/roches-alecensa-beats-xalkori-lung-cancer-head-head/

Novartis’ Zykadia gets fast first-line lung cancer review

February 24, 2017

Roche rival has Breakthrough Therapy status.

Novartis’ Zykadia gets fast first-line lung cancer review

https://pharmaphorum.com/news/novartis-zykadia-gets-fast-first-line-lung-cancer-review/

Roche’s Alecensa approved in Europe, with head-to-head data coming

February 21, 2017

Alecensa part of Roche’s goal of becoming dominant player in NSCLC

Roche’s Alecensa approved in Europe, with head-to-head data coming

https://pharmaphorum.com/news/alecensa/

With all eyes on IO, Tagrisso could be AZ’s ace card

February 2, 2017

AstraZeneca saw revenues decline by 3% and earnings per share fall 5% in 2016 as the expiry of

With all eyes on IO, Tagrisso could be AZ’s ace card

https://pharmaphorum.com/news/io-tagrisso-az-ace-card/

Merck soars on Keytruda combination filing

January 12, 2017

Approval by May could put Keytruda in pole position

Merck soars on Keytruda combination filing

https://pharmaphorum.com/news/merck-soars-keytruda-combination-filing/

Can Keytruda beat Opdivo to full UK access in lung cancer?

October 20, 2016

A decisive moment in lung cancer treatment is nearing

Can Keytruda beat Opdivo to full UK access in lung cancer?

https://pharmaphorum.com/news/keytruda-opdivo-uk-lung-cancer/

BMS and Nektar to pair Opdivo with natural killer cell drug

September 27, 2016

BMS and Nektar’s combination latest in frenzied immunotherapy field

BMS and Nektar to pair Opdivo with natural killer cell drug

https://pharmaphorum.com/news/bms-nektar-pair-opdivo-natural-killer-cell-drug/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

NSCLC

ASCO 2017: Breast cancer next target for Keytruda

BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cancer patients

Roche’s Alecensa beats Xalkori in lung cancer head-to-head

Novartis’ Zykadia gets fast first-line lung cancer review

Roche’s Alecensa approved in Europe, with head-to-head data coming

With all eyes on IO, Tagrisso could be AZ’s ace card

Merck soars on Keytruda combination filing

Can Keytruda beat Opdivo to full UK access in lung cancer?

BMS and Nektar to pair Opdivo with natural killer cell drug

Partnerships in Clinical Trials Europe | 28-29 November 2017 | RAI, Amsterdam

Inhalation and Respiratory Drug Products Summit

THET Annual Conference 2017

RA pill setback spoils Lilly’s growth story

Celgene hopes device + drug can tackle aggressive brain tumours

Tocagen’s brain tumour candidate gets PRIME designation

NHS should pay for medicines based on outcomes, argues Novartis-backed report

Amazon looks set to enter healthcare market

Managing chronic illness in children and adolescents

Health literacy ‘elephant in the room’ in patient engagement

The most notable digital health trends of 2017 so far

Europe has untapped medical innovation – but needs high speed connections to make it work

Healthcare’s hype cycle: which technologies will stay the course?

Search

Advanced Search

Trending

NSCLC